These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

370 related items for PubMed ID: 18484677

  • 21. Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications.
    Malak S, Labopin M, Saint-Martin C, Bellanne-Chantelot C, Najman A, French Group of Familial Myeloproliferative Disorders.
    Blood Cells Mol Dis; ; 49(3-4):170-6. PubMed ID: 22818858
    [Abstract] [Full Text] [Related]

  • 22. Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera.
    Ganly P, Hanrahan V, Baker B, Romeril K.
    Am J Hematol; 2007 Jan; 82(1):80-2. PubMed ID: 16924638
    [Abstract] [Full Text] [Related]

  • 23. Narrative review: Thrombocytosis, polycythemia vera, and JAK2 mutations: The phenotypic mimicry of chronic myeloproliferation.
    Spivak JL.
    Ann Intern Med; 2010 Mar 02; 152(5):300-6. PubMed ID: 20194236
    [Abstract] [Full Text] [Related]

  • 24. Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes.
    Stein BL, Williams DM, O'Keefe C, Rogers O, Ingersoll RG, Spivak JL, Verma A, Maciejewski JP, McDevitt MA, Moliterno AR.
    Haematologica; 2011 Oct 02; 96(10):1462-9. PubMed ID: 21712540
    [Abstract] [Full Text] [Related]

  • 25. Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers.
    Hussein K, Bock O, Kreipe H.
    Pathobiology; 2007 Oct 02; 74(2):72-80. PubMed ID: 17587878
    [Abstract] [Full Text] [Related]

  • 26. Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.
    Barbui T, Thiele J, Vannucchi AM, Tefferi A.
    Blood Cancer J; 2015 Aug 14; 5(8):e337. PubMed ID: 26832847
    [Abstract] [Full Text] [Related]

  • 27. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy.
    Tefferi A.
    Am J Hematol; 2008 Jun 14; 83(6):491-7. PubMed ID: 18429051
    [Abstract] [Full Text] [Related]

  • 28. JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.
    Duletić AN, Dekanić A, Hadzisejdić I, Kusen I, Matusan-Ilijas K, Grohovac D, Grahovac B, Jonjić N.
    Coll Antropol; 2012 Sep 14; 36(3):859-65. PubMed ID: 23213945
    [Abstract] [Full Text] [Related]

  • 29. Fast and reliable mutation detection of the complete exon 11-15 JAK2 coding region using non-isotopic RNase cleavage assay (NIRCA).
    Kambas K, Mitroulis I, Kourtzelis I, Chrysanthopoulou A, Speletas M, Ritis K.
    Eur J Haematol; 2009 Sep 14; 83(3):215-9. PubMed ID: 19500139
    [Abstract] [Full Text] [Related]

  • 30. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S, Michiels JJ.
    Semin Thromb Hemost; 2006 Jun 14; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [Abstract] [Full Text] [Related]

  • 31. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F.
    Shide K, Shimoda HK, Kumano T, Karube K, Kameda T, Takenaka K, Oku S, Abe H, Katayose KS, Kubuki Y, Kusumoto K, Hasuike S, Tahara Y, Nagata K, Matsuda T, Ohshima K, Harada M, Shimoda K.
    Leukemia; 2008 Jan 14; 22(1):87-95. PubMed ID: 18033315
    [Abstract] [Full Text] [Related]

  • 32. Prognostic factors and models in polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
    Passamonti F.
    Clin Lymphoma Myeloma Leuk; 2011 Jun 14; 11 Suppl 1():S25-7. PubMed ID: 22035744
    [Abstract] [Full Text] [Related]

  • 33. Myeloproliferative neoplasms.
    Publicover A, Medd P.
    Clin Med (Lond); 2013 Apr 14; 13(2):188-92. PubMed ID: 23681871
    [Abstract] [Full Text] [Related]

  • 34. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.
    Rumi E, Cazzola M.
    Blood; 2017 Feb 09; 129(6):680-692. PubMed ID: 28028026
    [Abstract] [Full Text] [Related]

  • 35. JAK2 V617F/C618R mutation in a patient with polycythemia vera: a case study and review of the literature.
    Yoo JH, Park TS, Maeng HY, Sun YK, Kim YA, Kie JH, Cho EH, Song J, Lee KA, Suh B, Choi JR.
    Cancer Genet Cytogenet; 2009 Feb 09; 189(1):43-7. PubMed ID: 19167611
    [Abstract] [Full Text] [Related]

  • 36. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
    Tefferi A.
    Am J Hematol; 2012 Mar 09; 87(3):285-93. PubMed ID: 22331582
    [Abstract] [Full Text] [Related]

  • 37. Polycythemia vera: scientific advances and current practice.
    Tefferi A, Spivak JL.
    Semin Hematol; 2005 Oct 09; 42(4):206-20. PubMed ID: 16210034
    [Abstract] [Full Text] [Related]

  • 38. JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms.
    Oh ST, Gotlib J.
    Expert Rev Hematol; 2010 Jun 09; 3(3):323-37. PubMed ID: 21082983
    [Abstract] [Full Text] [Related]

  • 39. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.
    Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A.
    Leukemia; 2008 Jul 09; 22(7):1299-307. PubMed ID: 18496562
    [Abstract] [Full Text] [Related]

  • 40. Low incidence of familial occurrence of thrombocythaemia and/or thrombocytosis.
    Randi ML, Fabris F, Visentin I, Girolami A.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988 Jul 09; 115(5):695-9. PubMed ID: 2465250
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.